Patents by Inventor James W. Darrow

James W. Darrow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8058446
    Abstract: At least one chemical entity chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof is described herein. Pharmaceutical compositions comprising at least one chemical entity of the invention, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
    Type: Grant
    Filed: September 11, 2007
    Date of Patent: November 15, 2011
    Assignee: Gilead Connecticut, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Jeffrey E. Kropf, Tony Lee, James W. Darrow, Scott A. Mitchell, Jianjun Xu, Aaron C. Schmitt
  • Publication number: 20110177011
    Abstract: Compounds of Formula I-a and all pharmaceutically-acceptable forms thereof, are described herein. The variables R1, R2, R3, Z1, Q, and A shown in Formula I-a are defined herein. Pharmaceutical compositions containing one or more compounds of Formula I-a, or a pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are provided herein. Methods of treating patients suffering from certain diseases responsive to inhibition of tyrosine kinase activity are also given. In certain embodiments the diseases are responsive to inhibition of Btk activity and/or B-cell proliferation. Such methods comprise administering to such patients an amount of a compound of Formula I-a effective to reduce signs or symptoms of the disease. These diseases include cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction.
    Type: Application
    Filed: January 23, 2008
    Publication date: July 21, 2011
    Inventors: Kevin S. Currie, Robert W. DeSimone, Scott A. Mitchell, Douglas A. Pippin, James W. Darrow, Xiaobing Qian, Mark Velleca, Dapeng Qian
  • Patent number: 7947835
    Abstract: At least one chemical entity chosen from compounds of Formula 2 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof is described herein. Pharmaceutical compositions comprising at least one chemical entity of the invention, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
    Type: Grant
    Filed: March 9, 2006
    Date of Patent: May 24, 2011
    Assignee: CGI Pharmaceuticals, Inc.
    Inventors: David R. Brittelli, Kevin S. Currie, James W. Darrow, Jeffrey E. Kropf, Seung H. Lee, Steven L. Gallion, Scott A. Mitchell, Douglas A. I. Pippin, Peter A. Blomgren, Douglas Gregory Stafford
  • Publication number: 20100160292
    Abstract: Methods of inhibiting BTK activity by inhibiting phosphorylation of Y551 of BTK, methods of treating patients by inhibiting BTK activity by inhibiting phosphorylation of Y551 of BTK, chemical entities that bind to BTK and inhibited complexes are provided.
    Type: Application
    Filed: September 11, 2007
    Publication date: June 24, 2010
    Applicant: CGI PHARMACEUTICALS, INC
    Inventors: James A. Whitney, Julie Di Paolo, Mark Velleca, David R. Brittelli, Kevin S. Currie, James W. Darrow, Jeffrey E. Krope, Seung H. Lee, Steven L. Gallion, Scott A. Mitchell, Doughlas A.I. Pippen, Peter A. Blomgren, Doughlas Gregory Stafford
  • Patent number: 7405295
    Abstract: Compounds of Formula I-a and all pharmaceutically-acceptable forms thereof, are described herein. The variables R1, R2, R3, Z1, Q, and A shown in Formula I-a are defined herein. Pharmaceutical compositions containing one or more compounds of Formula I-a, or a pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are provided herein. Methods of treating patients suffering from certain diseases responsive to inhibition of tyrosine kinase activity are also given. In certain embodiments the diseases are responsive to inhibition of Btk activity and/or B-cell proliferation. Such methods comprise administering to such patients an amount of a compound of Formula I-a effective to reduce signs or symptoms of the disease. These diseases include cancer, an autoimmune and/or inflammatory disease, or an acute inflammatory reaction.
    Type: Grant
    Filed: June 4, 2004
    Date of Patent: July 29, 2008
    Assignee: CGI Pharmaceuticals, Inc.
    Inventors: Kevin S. Currie, Robert W. DeSimone, Scott A. Mitchell, Douglas A. Pippin, James W. Darrow, Xiaobing Qian, Mark Velleca, Dapeng Qian
  • Publication number: 20080139557
    Abstract: At least one chemical entity chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof is described herein. Pharmaceutical compositions comprising at least one chemical entity of the invention, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
    Type: Application
    Filed: September 11, 2007
    Publication date: June 12, 2008
    Inventors: Peter A. Blomgren, Kevin S. Currie, Jeffrey E. Kropf, Tony Lee, James W. Darrow, Scott A. Mitchell, Jianjun Xu, Aaron C. Schmitt
  • Publication number: 20080125417
    Abstract: At least one chemical entity chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof, is described herein. Pharmaceutical compositions comprising at least one chemical entity of Formula 1, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
    Type: Application
    Filed: September 11, 2007
    Publication date: May 29, 2008
    Inventors: Kevin S. Currie, Tony Lee, James W. Darrow, Peter A. Blomgren
  • Patent number: 7312341
    Abstract: A novel composition comprises a compound of Formula 1 the pharmaceutically acceptable salts, hydrates, solvates, crystal forms, diastereomers, prodrugs, or mixtures thereof. The composition is of particular utility in the treatment of kinase-implicated disorders.
    Type: Grant
    Filed: September 9, 2003
    Date of Patent: December 25, 2007
    Assignee: CGI Pharmaceuticals, Inc.
    Inventors: Robert W. DeSimone, Douglas A. Pippin, James W. Darrow, Scott A. Mitchell, Kevin S. Currie
  • Patent number: 7259164
    Abstract: Certain substituted imidazo[1,2-a]pyrazines and the pharmaceutically acceptable salts thereof, are provided herein. Pharmaceutical compositions containing one or more compound of Formula I, or a pharmaceutically acceptable salt of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to EphB4 kinase modulation, which comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder are disclosed. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with one or more other therapeutic agents.
    Type: Grant
    Filed: August 11, 2004
    Date of Patent: August 21, 2007
    Assignee: CGI Pharmaceuticals, Inc.
    Inventors: Scott A. Mitchell, Robert W. DeSimone, James W. Darrow, Douglas A. Pippin, M. Diana Danca
  • Patent number: 7160885
    Abstract: This invention pertains to compounds of Formula I: and the pharmaceutically-acceptable forms thereof. The variables R1, R2, R3, Z1, Z2, W, and X shown in Formula I are defined herein. The invention also provides pharmaceutical compositions containing one or more compound of Formula I, or pharmaceutically acceptable form of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain diseases and disorders responsive to Hsp90 complex modulation, which comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These diseases include cancer, including chronic myeloid leukemia, melanoma, breast, ovarian, brain, thyroid, colorectal, prostate, and bladder cancer, heart disease, stroke, autoimmune/inflammatory diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: January 9, 2007
    Assignee: CGI Pharmaceuticals, Inc.
    Inventors: Kevin S. Currie, Robert W. DeSimone, Douglas A. Pippin, James W. Darrow, Scott A. Mitchell
  • Patent number: 7015227
    Abstract: A composition comprises a compound of Formula 1: a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof, wherein W is a nitrogen-substituted 5- or 6-membered monocyclic ring. The compounds are of utility as modulators of kinase activity.
    Type: Grant
    Filed: June 23, 2003
    Date of Patent: March 21, 2006
    Assignee: CGI Pharmaceuticals, Inc.
    Inventors: James W. Darrow, Robert W. DeSimone, Douglas A. Pippin, Scott A. Mitchell
  • Patent number: 6919340
    Abstract: A novel composition comprises a compound of Formula 1 the pharmaceutically acceptable salts, hydrates, solvates, crystal forms, diastereomers, prodrugs, or mixtures thereof. The composition is of particular utility in the treatment of kinase-implicated disorders.
    Type: Grant
    Filed: April 21, 2003
    Date of Patent: July 19, 2005
    Assignee: Cellular Genomics, Inc.
    Inventors: Kevin S. Currie, Robert W. DeSimone, Douglas A. Pippin, James W. Darrow, Scott A. Mitchell
  • Publication number: 20040082627
    Abstract: Compound having Formula 1: 1
    Type: Application
    Filed: June 23, 2003
    Publication date: April 29, 2004
    Inventors: James W. Darrow, Robert W. DeSimone, Douglas A. Pippin, Scott A. Mitchell
  • Publication number: 20040067951
    Abstract: A novel composition comprises a compound of Formula 1 1
    Type: Application
    Filed: September 9, 2003
    Publication date: April 8, 2004
    Inventors: Robert W. DeSimone, Douglas A. Pippin, James W. Darrow, Scott A. Mitchell, Kevin S. Currie
  • Publication number: 20040053927
    Abstract: A composition comprises a compound of Formula 1: 1
    Type: Application
    Filed: June 23, 2003
    Publication date: March 18, 2004
    Inventors: James W. Darrow, Robert W. DeSimone, Douglas A. Pippin, Scott A. Mitchell
  • Publication number: 20030212073
    Abstract: A novel composition comprises a compound of Formula 1 1
    Type: Application
    Filed: April 21, 2003
    Publication date: November 13, 2003
    Inventors: Kevin S. Currie, Robert W. DeSimone, Douglas A. Pippin, James W. Darrow, Scott A. Mitchell
  • Publication number: 20030105117
    Abstract: Disclosed are compounds of the formula: 1
    Type: Application
    Filed: August 27, 2002
    Publication date: June 5, 2003
    Applicant: Neurogen Corporation
    Inventors: Raymond F. Horvath, James W. Darrow, George D. Maynard
  • Publication number: 20030069246
    Abstract: Disclosed are compounds of the formula: 1
    Type: Application
    Filed: February 25, 2002
    Publication date: April 10, 2003
    Applicant: Neurogen Corporation
    Inventors: James W. Darrow, Stephane J. De Lombaert, Charles A. Blum, Jennifer N. Tran, Mark A. Giangiordano, David Andrew Griffith, Philip Albert Carpino
  • Patent number: 6476038
    Abstract: Disclosed are compounds of the formula: where R1, R2, R3, R4, R5, R6, and X are defined herein. These compounds are selective modulators of NPY1 receptors. These compounds are useful in the treatment of a number of CNS disorders, metabolic disorders, and peripheral disorders, particularly eating disorders and hypertension. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of NPY1 receptors and as standards in assays for NPY1 receptor binding. Methods of using the compounds in receptor localization studies are given.
    Type: Grant
    Filed: September 29, 2000
    Date of Patent: November 5, 2002
    Assignees: Neurogen Corporation, Pfizer Inc.
    Inventors: James W. Darrow, St├ęphane De Lombaert, Charles Blum, Jennifer Tran, Mark Giangiordano, David Andrew Griffith, Philip Albert Carpino
  • Patent number: 6472402
    Abstract: Disclosed are compounds of the formula: wherein Ar, R1, W, X and m are substituents as defined herein.
    Type: Grant
    Filed: September 30, 1999
    Date of Patent: October 29, 2002
    Assignee: Neurogen Corporation
    Inventors: Raymond F. Horvath, James W. Darrow, George D. Maynard